moxetumomab pasudotox   Click here for help

GtoPdb Ligand ID: 7675

Synonyms: CAT-8015 | GCR-8015 | HA22 | Lumoxiti® | moxetumomab pasudotox-tdfk
Approved drug Immunopharmacology Ligand
moxetumomab pasudotox is an approved drug (FDA (2018), EMA (2021))
Compound class: Antibody
Comment: Peptide sequence information for this antibody is available from its IMGT/mAb-DB link. The moxetumomab monoclonal has been mutated to increase affinity for CD22 [6] (patent WO2003027135[1]), and the antibody is fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38) [2,4] (patent US7982011 [5]). The Uniprot accession for Pseudomonas exotoxin-A is P11439.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Beers R, Kreitman RJ, Pastan IH, Salvatore G. (2003)
Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells.
Patent number: WO2003027135. Assignee: Beers R, Kreitman RJ, Pastan IH, Salvatore G, US Gov Health & Human Serv. Priority date: 26/09/2001. Publication date: 03/04/2003.
2. Kreitman RJ, Pastan I. (2011)
Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.
Clin Cancer Res, 17 (20): 6398-405. [PMID:22003067]
3. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I. (2012)
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.
J Clin Oncol, 30 (15): 1822-8. [PMID:22355053]
4. Onda M, Nagata S, FitzGerald DJ, Beers R, Fisher RJ, Vincent JJ, Lee B, Nakamura M, Hwang J, Kreitman RJ et al.. (2006)
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
J Immunol, 177 (12): 8822-34. [PMID:17142785]
5. Pastan IH, Ho M, Bang S. (2011)
Mutated anti-cd22 antibodies and immunoconjugates.
Patent number: US7982011. Assignee: The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services. Priority date: 25/11/2003. Publication date: 19/07/2011.
6. Salvatore G, Beers R, Margulies I, Kreitman RJ, Pastan I. (2002)
Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
Clin Cancer Res, 8 (4): 995-1002. [PMID:11948105]
7. Yates SP, Merrill AR. (2004)
Elucidation of eukaryotic elongation factor-2 contact sites within the catalytic domain of Pseudomonas aeruginosa exotoxin A.
Biochem J, 379 (Pt 3): 563-72. [PMID:14733615]